
Every software or AI vendor that fails to get into the NHS blames the same three things. Long sales cycles. Trust issues. Budget. All three are effects, not causes.
The cause is two gates.
The first gate is legal deployability. Can this product actually be deployed inside an NHS environment without triggering an Information Governance escalation, a DTAC failure, a DPIA rewrite, or a Clinical Safety officer refusal? If any of those apply, the sale never happens because the product cannot land.
The second gate is commercial viability. Even if you can technically deploy, who is the buyer, what is their budget line, what evidence do they need before they part with it, and how long does that decision take? If the buying centre is not real, the price point does not fit an existing budget, or the evidence bar is too high, the sale still does not happen.
These two gates are non-negotiable. You do not sell your way past them. You clear them, or you do not sell.
Most vendors I meet spend eighteen months and three million pounds trying to sell past gates they have not cleared. The pipeline slide grows. The revenue does not. The next board meeting is the same board meeting as the last one.
Ortent published a diagnostic on this last week. It sits at ortent.co/tools/nhs-readiness.
Twenty questions. Ten minutes. Two axes: deployable and sellable. A five-stage maturity model on each. The output is a read on where you are and the single next gate you have to clear. Not a shopping list. One gate.
Built from Ortent’s NHS body of knowledge across more than a decade of software and AI deployments into the NHS, some of which shipped and some of which did not. What ships tends to follow the same shape. What does not tends to fail in the same ways.
Two ways to use it.
Take it as a founder. If you are ten to eighteen months from an NHS pilot and cannot answer twenty operator-level questions on where you stand, the eighteen months are already at risk. Better to see it now than after the pilot slips.
Take it as an operator or commercial lead. Score independently. Have your CTO or clinical lead score the deployability side. Have your CCO or sales lead score the sellable side. The disagreements are where the truth is.
The tool is instant, needs no email, and nothing leaves your browser. There is a fifteen-page whitepaper alongside it, and a Claude project you can install if you would rather run the diagnostic conversationally.
If you sell software or AI into the NHS, or you sit on the board of a company that does, this is worth ten minutes.
One warning. The tool does not lie. If it tells you the deployability axis is at Stage 2 while your board slide shows a pilot signed for Q2, the board slide is wrong. Better to know that now than in the QBR.